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Abstract Echogenic liposomes (ELIP), that can encap-
sulate both recombinant tissue-type plasminogen activator
(rt-PA) and microbubbles, are under development to im-
prove the treatment of thrombo-occlusive disease. How-
ever, the enzymatic activity, thrombolytic efficacy, and
stable cavitation activity generated by this agent has yet to
be evaluated and compared to another established ultra-
sound-enhanced thrombolytic scheme. A spectrophoto-
metric method was used to compare the enzymatic activity
of the rt-PA incorporated into ELIP (t-ELIP) to that of rt-
PA. An in vitro flow model was employed to measure the
thrombolytic efficacy and dose of ultraharmonic emissions
from stable cavitation for 120-kHz ultrasound exposure of
three treatment schemes: rt-PA, rt-PA and the perfluoro-
carbon-filled microbubble Definity, and t-ELIP. The en-
zymatic activity of rt-PA incorporated into t-ELIP was
28 % that of rt-PA. Thrombolytic efficacy of t-ELIP or rt-
PA and Definity was equivalent when the dose of t-ELIP
was adjusted to produce comparable enzymatic activity.
Sustained bubble activity was nucleated from Definity but
not from t-ELIP exposed to 120-kHz ultrasound. These
results emphasize the advantages of encapsulating a
thrombolytic and the importance of incorporating an
insoluble gas required to promote sustained, stable
cavitation activity.
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Introduction
Stroke is currently the fourth leading cause of death in the
United States of America [1], and a leading cause of death
worldwide [2]. The only FDA-approved thrombolytic drug,
recombinant tissue-type plasminogen activator (rt-PA), is
administered only in 1.5 % of cases [1] due to potential
bleeding complications and strict exclusion criteria [3].
Thus, targeted delivery of this potent thrombolytic is an
attractive concept, with implications for treatment of
thrombo-occlusive disease.
Echogenic liposomes (ELIP) containing gas microbub-
bles have been developed as a vector for therapeutic drugs
[4]. Thrombolytic-loaded liposomes, termed t-ELIP, target
fibrin [5], and can be acoustically activated [6, 7] for local-
ized drug delivery. Encapsulation of rt-PA may reduce sys-
temic toxicity compared to direct intravenous injection of
this potent thrombolytic. Furthermore, ultrasound insonation
of the gasmicrobubbleswithin t-ELIP can potentially release
the rt-PA locally and incite stable cavitation [8]. Stable
cavitation activity is known to be correlated with ultrasound
enhancement of rt-PA thrombolysis [9, 10]. Thus, t-ELIP has
the potential to target the clot, deliver rt-PA locally, and
enhance thrombolytic efficacy.
Thrombolytic-loaded t-ELIP have been shown to enhance
thrombolysis compared to rt-PA in vitro in a static fluid
system [6, 11]. A limitation of the in vitro models employed
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by Shaw et al. and Tiukinhoy-Laing et al. was the absence of
flow, which may influence both thrombolytic efficacy [12]
and cavitation activity [13]. Equivalent thrombolytic effi-
cacy of t-ELIP and rt-PA has been demonstrated in an in vivo
rabbit model [14]. The type and amount of cavitation activity
nucleated by 120-kHz insonation of t-ELIP, however, has not
previously been investigated.
The objective of this study was therefore to explore the
relationship between thrombolytic efficacy, cavitation
emissions, and the enzymatic activity of rt-PA-loaded ELIP.
Here, an in vitro flow model [10, 15] was used to study
thrombolytic efficacy and stable cavitation emissions in real-
time during t-ELIP sonothrombolysis. The maximum lytic
rate, time to 50 % clot width reduction, and percent reduc-
tion in clot width over 30 min were used as metrics of
thrombolytic efficacy. In addition, the enzymatic activity of
rt-PA was measured before and after its loading into ELIP.
Materials and methods
Preparation of human fresh frozen plasma and rt-
PA
Human fresh-frozen plasma (hFFP) was procured from a
blood bank (Hoxworth Blood Center, Cincinnati, OH).
Thirty milliliter aliquots of the hFFP were thawed for each
experiment and allowed to reach atmospheric gas equilib-
rium at 37 C in an open container for 2 h. rt-PA was
obtained from the manufacturer (Activase, Genentech,
San Fransisco, CA, USA) as lyophilized power. Each vial
was mixed with sterile water to a concentration of 1 mg/
mL as per manufacturer instructions, aliquoted into 1.0 mL
centrifuge tubes, and stored at -80 C. The enzymatic
activity of rt-PA is stable over a period of 7 years using this
protocol [16].
Preparation of blood clots
Human whole blood clots were manufactured around silk
sutures following a protocol developed by Shaw et al. [17].
Following local Institutional Review Board approval and
written informed consent, venous human whole blood was
drawn from a pool of 10 healthy volunteers. Aliquots of
500 lL were transferred to sterile glass tubes containing
borosilicate glass micropipettes (1.12 mm inner diameter,
World Precision Instruments, Inc., USA), pre-threaded
with 7-0 silk sutures (Ethicon Industries, Cornelia, GA).
The blood was allowed to clot around the silk suture at
37 C for 3 h. Following clot formation, the tubes were
stored at 5 C for a minimum of 3 days to allow for
maximal clot retraction [6], lytic resistance, and stability
[18]. Before each measurement, the micropipette was
removed to produce a cylindrical clot adherent to the su-
ture. The initial clot size (550 ± 43 lm) was smaller than
that of the middle cerebral artery (2.4–4.6 mm) [19], the
site of occlusion for the majority of ischemic strokes [20].
However, the clot size is comparable to the perforating
branches of the middle cerebral artery (80–840 lm) [21],
which are highly vulnerable to occlusion.
Preparation of ultrasound contrast agents (UCAs)
Vials of Definity (perflutren lipid microspheres; Lantheus
Medical Imaging, N. Billerica, MA, UCA), containing
octofluoropropane encapsulated microbubble by a lipid
monolayer shell, were activated according to the manufactur-
er’s instructions. The vial was stored at 5 C until needed. The
vial was allowed to warm to room temperature (20–24 C) for
one hour prior to activation by shaking for 45 s using a Vial-
Mix (Lantheus Medical Imaging). The agent was diluted to a
final concentration of 2 lL/mL (1 9 104 particles/mL). This
number density is consistent with the manufacturer’s recom-
mendeddose (LantheusMedical Imaging,Billerica,MA,USA)
for left ventricular opacification.
Preparation of rt-PA loaded echogenic liposomes
rt-PA-loaded ELIP (t-ELIP) were prepared at the Univer-
sity of Texas Health Science Center, Houston, as described
by Huang et al. [22] and shipped to the University of
Cincinnati on dry ice. Each vial containing 2 mg of lyo-
philized lipids and 80 lg of rt-PA was reconstituted with
0.2 lL of 0.2 lm filtered deionized water (NANOPure,
Barnstead International, Dubuque, IA, USA), and diluted in
hFFP within 5 min of reconstitution to achieve rt-PA
concentrations of 0.32, 1.58, and 3.15 lg/mL (lipid con-
centrations of 8.0, 39.5, and 78.7 lg/mL, respectively).
rt-PA activity measurement
The enzymatic activity of rt-PA and t-ELIP were measured
using a spectrophotometric method [7, 23]. Thawed rt-PA
or reconstituted t-ELIP were diluted into a solution of
0.5 % BSA and 1 % Triton-X (Sigma-Aldrich, St. Louis,
MO, USA) to achieve concentrations of rt-PA between 0.3
and 3 lg/mL in disposable cuvettes used for spectropho-
tometric measurement. The amount of Triton-X employed
in the solution exceeded the critical micelle concentration
(0.015 %) (Triton-X Product Information Sheet, Sigma-
Aldrich, St. Louis, MO, USA) to ensure rupture of the lipid
shell surrounding t-ELIP and release of the associated rt-
PA. The solution was aspirated to remove echogenic mi-
crobubbles [24], and diluted into a pre-warmed solution
(37 C) of 0.5 % phosphate buffer solution and a chro-
mogenic substrate (S-2288, Chromogenix, DiaPharma
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Group, Inc., Westchester, OH, USA). The chromogenic
substrate is hydrolyzed by rt-PA and allows spectropho-
tometrical measurement of the change of absorbance at
405 nm over time, which is proportional to the enzymatic
activity of rt-PA. A spectrophotometer (UV-1700, Shi-
madzu, Japan) with temperature controller (TCC-240A,
Shimadzu, Japan) was used to record the absorbance of the
solution over the course of 5 min at 37 C. The rt-PA ac-
tivity was reported in terms of the change in absorbance
over time (DAbs/min).
In vitro flow phantom
The invitro flowmodel depicted inFig. 1was based onCheng
et al. [25] and Gruber et al. [15], and was used to quantify
thrombolytic efficacyand stable cavitationactivity.Anacrylic
tank (16 9 33 9 9 cm) was filled with approximately 3 L of
degassed (20 ± 5 % dissolved oxygen), reverse-osmosis
water heated to 37.3 ± 0.3 C. The water was continuously
filtered (0.2 lm), and the gas content and temperature were
maintained throughout the experiment with a custom-built
recirculation system. The walls of the tank were lined with a
1 cm thick acoustic absorber (Aptflex F48, Precision Acous-
tics, Dorchester, Dorset, UK).
The flow channel consisted of low-density polyethylene
tubing (inner diameter 1.6 mm, outer diameter 3.2 mm, part
1 J-109-10, Freelin Wade Co., McMinnville, OR, USA) to
direct the plasma and therapeutics from a reservoir to a glass
micropipette (2.15 mm inner diameter, 0.3 mm wall thick-
ness 5-000-2200, Drummond Scientific Co., Broomall, PA,
USA). A clot was mounted along the central axis of the
micropipette by snuggly fitting the suture at the ends of the
micropipette with latex tubing. The micropipette was posi-
tioned over a microscope slide (Fisherbrand, 12-550C,
Fisher Scientific, Pittsburg, PA, USA) on the bottom of the
tank to allow imaging of the clot with an invertedmicroscope
(IX71, Olympus Corporation, Center Valley, PA, USA). The
focal area of the objective (UPlanFLN 10X, 10 mmworking
distance, Olympus Corporation, Center Valley, PA, USA)
was approximately 1200 9 900 lm. Images were captured
by a CCD camera (Retiga-2000R, Q Imaging, Surrey, BC,
Canada) at a rate of 2.33 Hz. Flow was maintained at
0.65 mL/minwith a programmable syringe pump (model 44,
Harvard Apparatus Co. Inc., South Natick, MA, USA) in
continuouswithdrawalmode. This flow rate is in the range of
physiologic flow rates measured in the occluded middle
cerebral artery during ischemic stroke [26].
Ultrasound exposure and cavitation detection
A custom-designed 120-kHz transducer (H160, Sonic
Concepts, Inc. Woodburn, WA, USA) was used to insonate
the clot and the perfusate within the micropipette. The
unfocused transducer element (30 mm diameter aperture)
was excited at its resonant frequency of 120 kHz with a
function generator (33250A, Agilent Technologies, Inc.,
Santa Clara, CA, USA) and power amplifier (1040L, ENI,
Rochester, NY, USA). A custom-built impedance matching
network (Sonic Concepts, Inc. Woodburn, WA, USA)
maximized power transfer to the transducer. The acoustic
field was measured and the in situ acoustic pressure
calibrated along the clot with a 0.5-mm hydrophone (TC
4038, Teledyne Reson Inc. Goleta, CA, USA) mounted on
a computer-controlled three-axis positioner (NF-90, Vel-
mex Inc., Bloomfield, NY, USA).
Ultraharmonic (UH) emissions, a key acoustic signature
of stable cavitation [27], were monitored with a passive
cavitation detector (PCD) aligned confocal with the clot.
The PCD, a 19-mm-diameter circular single-element, long-
focus 2.25-MHz transducer (595516C, Picker Roentgen
GmbH, Espelkamp, Germany), has previously been uti-
lized to detect cavitation generated by 120-kHz insonation
[10, 27]. The signal received from the PCD was filtered by
a 10-MHz low-pass filter (J73E, TTE Inc, Los Angeles,
CA, USA) to remove noise from radiofrequency interfer-
ence, and amplified with a wideband low-noise amplifier
(CLC100, Cadeka Microcircuits LLC, Colorado, USA).
The signal was digitized (10 ms duration, 31.25 MHz
sampling frequency), and the power spectrum computed in
MATLAB (The Mathworks, Natick, MA, USA). UH
bands [13] of the power spectrum between 250 kHz and
1 MHz were summed over a 2-kHz bandwidth centered
around each UH. The choice of these frequency bands for
the characterization of stable cavitation activity was de-
tailed in a previous study [15]. The UH dose for a given
experiment is defined here as the integration of the UH
power detected over the 30 min experiment duration.
An intermittent ultrasound exposure scheme, as de-
scribed previously [13], was employed to maximize the UH
dose over the 30 min treatment duration. A peak-to-peak
pressure of 0.44 MPa and insonation period of 50 s were











Fig. 1 Side view of experimental set for observations of ultrasound-
enhanced thrombolysis. Flow is out of the page
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treatment duration [10]. The insonation period was fol-
lowed by a 30 s quiescent period to allow a fresh influx of
Definity or t-ELIP to fill the micropipette. Insonation and
quiescent periods were continuously repeated during the
30 min treatment.
Experimental procedure
A clot was mounted in the capillary tube, and submerged in
the temperature-controlled fluid within the tank. The po-
sition of the tank was adjusted so that the clot could be
visualized by the microscope objective. The focus of the
PCD was aligned with the capillary tube. Clots were
treated for 30 min. The experiments were distributed into 3
controls: (1) plasma alone; (2) plasma and optimized in-
termittent ultrasound exposure (0.44 MPa peak-to-peak
continuous wave, 50 s on, 30 s off); and (3) plasma plus
Definity (2 lL/mL) and optimized intermittent ultrasound
exposure and 5 treatment types: (1) rt-PA alone; (2) t-ELIP
alone; (3) rt-PA and the optimized intermittent ultrasound
scheme; (4) rt-PA and Definity and the optimized inter-
mittent ultrasound scheme; and (5) t-ELIP and the opti-
mized intermittent ultrasound scheme. For each treatment,
rt-PA concentrations of 0, 0.32, 1.58, and 3.15 lg/mL were
investigated. These rt-PA concentrations are within the
therapeutic concentration range in humans [28]. Images
and acoustic emissions recorded by the PCD were acquired
at a rate of 2.33 Hz (0.43 s inter-frame time), and stored for
analysis offline. A total of 12 experiments (using clots from
four different donors) were performed for a given treatment
type and concentration of rt-PA (180 total experiments).
Clot diameter determination
Images of the clots were used to determine thrombolytic
efficacy [25]. The clot edges were tracked using an edge-
detection routine following Meunier et al. [29]. The clot
diameter for a given frame, d, was defined as the average
distance between the detected edges for each row of the
image (600 rows total, 900 lm total length), minus the
diameter of the suture (95 ± 15 lm).
The fractional clot loss, FCL, was defined as the percent
reduction of the clot diameter at the conclusion of the
measurement compared to the initial clot diameter:
FCL ¼ 100 
d t0ð Þ  dðt30Þ
dðt0Þ
ð1Þ
where dðtÞ is the clot diameter at time t, the subscript ‘0’
indicates the initial time point, and the subscript ‘30’
indicates the 30 min time point. The time-dependent re-
duction in clot width, KðtÞ, was fit in the least squares sense
to a sigmoidally-decreasing function [30]:
K tð Þ ¼ 100 100
1þ ebðtt50Þ ð2Þ
where b and t50 are fitting parameters. The time to a 50 %
reduction in clot width occurs at t ¼ t50. Themaximum slope
(i.e. the lytic rate) of Eq. (1) occurs as t approaches t50. Using
a Taylor expansion of Eq. (2) around jt  t50j  1, the
maximum lytic rate, LRMAX , can be determined as:
LRMAX ¼ 25b: ð3Þ
Statistical analysis
Statistical analysis was performed using the MATLAB
Statistical Toolbox (The Mathworks, Natick, MA, USA).
Statistical differences in means of the fractional clot loss,
maximum lytic rate, and time to 50 % clot width reduction
between treatment types at each concentration of rt-PA
were determined by one-way unbalanced ANOVA with an
a level of 0.05. Adjusted p values based on Tukey’s HSD
test are reported to elucidate significant differences be-
tween the means of treatment cohorts. The correlation
between the fractional clot loss at 30 min, the maximum
lytic rate, and the time to 50 % clot width reduction and rt-
PA concentration were calculated using the Spearman’s
rank correlation coefficient in MATLAB (The Math-
works, Natick, MA, USA). A p\ 0.05 was used as a re-
quirement for significant correlation.
Results
Functional form for reduction in clot width
A representative example for the reduction in clot width
over the 30 min treatment period, along with the least
squares fit of the sigmoidal decrease given by Eq. (2), is
shown in Fig. 2. The coefficient of determination (r2) for
the sigmoidal function was 0.84 ± 0.21 for all the data
sets, indicating a good fit. In the absence of rt-PA, the clot
width was not well described by a sigmoidal decrease
(r2 = 0.59 ± 0.30). Thus, only the fractional clot loss is
reported for the thrombolytic efficacy of data acquired in
the absence of rt-PA (see Figs. 3c, 6c).
Maximum lytic rate and time to 50 % reduction
in clot width
The maximum lytic rates, defined in Eq. (3), for each treat-
ment type are shown in Fig. 3a, and corresponding p values
between the groups are reported in Table 1. Ultrasound ex-
posure of rt-PA, and Definity had the largest maximum
lytic rate on average at all concentrations of rt-PA. However,
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it was only larger than all groups at 1.58 lg/mL rt-PA. The
time to 50 % reduction in clot width, the fitting parameter t50
in Eq. (2), was lowest on average for rt-PA and Definity
exposed to 120-kHz ultrasound, as shown in Fig. 3b. Table 2
shows that t50 for 120-kHz ultrasound exposure of rt-PA and
Definity was not significantly lower than rt-PA alone, or
120-kHz ultrasound exposure of rt-PA. The maximum lytic
rate significantly increased with rt-PA concentration for all
cohorts except rt-PA and Definity exposed to 120-kHz ul-
trasound. The time to 50 % reduction in clot width sig-
nificantly decreased with rt-PA concentration for all cohorts
except rt-PA alone. The maximum lytic rate and t50 were not
reported in the absence of rt-PA due to the poor fit of Eq. (2)
to the clot width reduction.
Fractional clot loss
The fractional clot loss (FCL), defined by Eq. (1), for each
treatment type is shown in Fig. 3c. The FCL was typically
less than 5 % for all treatment arms in the absence of rt-
PA. As indicated in Table 3, 120-kHz ultrasound exposure
of rt-PA and Definity typically yielded a significantly
larger FCL than all cohorts. Ultrasound exposure did not
significantly increase the FCL of t-ELIP over t-ELIP alone.
Similarly, ultrasound exposure did not significantly in-
crease the FCL of rt-PA compared to rt-PA alone. The FCL
of t-ELIP and ultrasound exposure was not significantly
larger than rt-PA alone at any concentration of rt-PA. The
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cFig. 3 Thrombolytic efficacy data for rt-PA, rt-PA and Definity, and
t-ELIP at each target concentration of rt-PA, with and without
intermittent 120-kHz ultrasound exposure (US). aMaximum lytic rate
for all treatment arms determined using Eq. (3), with p values
indicated in Table 1. b Time to 50 % clot width reduction,
determined from Eq. (2), with p values indicated in Table 2.
c Fractional clot loss at the completion of the treatment (30 min),
using Eq. (1), with p values indicated in Table 3. The asterisks (*)
shown in a and c indicate the treatment arm is greater (p\ 0.05) than
all other treatment arms for that particular rt-PA concentration. The
lipid concentration of t-ELIP is indicated on the top abscissa label.
The sample size for each treatment (n) is 12
Fig. 2 Representative reduction in clot width over the course of a
30 min treatment (120-kHz ultrasound exposure of 0.32 mg/mL rt-PA
and Definity). The solid, red line is the least-squares fit of the data to
the sigmoidally decreasing function, Eq. (2), and the dashed, red lines
are the 95 % confidence intervals of the fit to the data
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Cavitation emissions
The UH dose from exposure to 120-kHz ultrasound of rt-
PA, or rt-PA and Definity, or t-ELIP is shown in Fig. 4.
Definity produced larger UH emissions at all concentra-
tions of rt-PA. Insonation of t-ELIP produced larger UH
emissions than insonation of rt-PA, except at the highest
concentration of rt-PA (3.15 lg/mL). However, the UH
dose of t-ELIP was still two-orders of magnitude less than
Definity at each concentration of rt-PA. The UH dose
increased as a function of rt-PA concentration for in-
sonation of rt-PA alone, but not t-ELIP or rt-PA and
Definity.
rt-PA activity
The rt-PA enzymatic activity as a function of rt-PA concentra-
tion for rt-PA and t-ELIP is shown in Fig. 5. The encapsulation
efficiency of t-ELIP, determined by comparing the enzymatic
activity in the absence and presence of Triton-X at 1 lg/mL,
was 59 %. The activity of both rt-PA and t-ELIP depended
linearly on the target concentration of rt-PA (r2 = 0.98 for both
t-ELIP and rt-PA). However, the slope of t-ELIP was smaller
than that of rt-PA (3.71 ± 0.23 DmAbs/min for t-ELIP vs.
13.24 ± 1.77 DmAbs/min for free rt-PA). Thus, the activity of
rt-PA from the t-ELIP solution was approximately 28 % that of
rt-PA for a given concentration of rt-PA.
Table 1 The Tukey’s HSD test
adjusted p values comparing the
treatment arms for the
maximum lytic rate, as shown in
Fig. 3a
rt-PA rt-PA ? US tELIP tELIP ? US
0.32 lg/mL
rt-PA ? US 1.00 – – –
tELIP 0.95 0.90 – –
tELIP ? US 1.00 1.00 0.84 –
rt-PA ? US ? Definity 0.06 0.08 0.00 0.03
1.58 lg/mL
rt-PA ? US 1.00 – – –
tELIP 0.95 0.99 – –
tELIP ? US 0.99 1.00 1.00 –
rt-PA ? US ? Definity 0.00 0.00 0.00 0.00
3.15 lg/mL
rt-PA ? US 1.00 – – –
tELIP 1.00 1.00 – –
tELIP ? US 1.00 1.00 0.35 –
rt-PA ? US ? Definity 0.02 0.16 0.00 0.36
Bold values indicate a significant difference between the treatment arms
Table 2 The Tukey’s HSD test
adjusted p values comparing the
treatment arms for the time to
50 % clot width reduction, as
shown in Fig. 3b
rt-PA rt-PA ? US tELIP tELIP ? US
0.32 lg/mL
rt-PA ? US 1.00 – – –
tELIP 0.02 0.01 – –
tELIP ? US 0.83 0.72 0.08 –
rt-PA ? US ? Definity 0.45 0.56 0.00 0.02
1.58 lg/mL
rt-PA ? US 1.00 – – –
tELIP 0.06 0.10 – –
tELIP ? US 0.28 0.42 0.73 –
rt-PA ? US ? Definity 0.56 0.57 0.00 0.01
3.15 lg/mL
rt-PA ? US 0.99 – – –
tELIP 0.99 0.88 – –
tELIP ? US 0.57 0.92 0.21 –
rt-PA ? US ? Definity 0.02 0.11 0.00 0.21
Bold values indicate a significant difference between the treatment arms
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FCL comparison for equal activities
Additional data sets were taken with the t-ELIP concen-
tration adjusted to give equivalent activity of rt-PA activity
at 0.32 and 1.58 lg/mL based on the activity measure-
ments shown in Fig. 5. The initial lytic rate, maximum
lytic rate, time to 50 % reduction in clot width, and frac-
tional clot loss at 30 min are shown in Fig. 6, and
corresponding p values are shown in Tables 4, 5 and 6. In
general, 120-kHz ultrasound exposure of rt-PA and
Definity cohort exhibited maximal thrombolysis (i.e.
greatest FCL, maximum lytic rate, and shortest time to
Fig. 4 The ultraharmonic dose, defined as the summation of
ultraharmonic emissions over the 30 min treatment duration, shown
for all cohorts employing 120-kHz insonation at all concentrations of
rt-PA. The asterisk (*) indicates the treatment arm is significantly
greater (p\ 0.05) than all other treatment arms for a given
concentration of rt-PA. The lipid concentration of t-ELIP is indicated
on the top abscissa. The sample size for each treatment (n) is 12
Table 3 The Tukey’s HSD test
adjusted p values comparing the
treatment arms for the fractional
clot loss, as shown in Fig. 3c
rt-PA rt-PA ? US tELIP tELIP ? US
0 lg/mL
rt-PA ? US 0.99 – – –
tELIP – – – –
tELIP ? US – – – –
rt-PA ? US ? Definity 0.86 0.93 – –
0.32 lg/mL
rt-PA ? US 1.00 – – –
tELIP 0.58 0.44 – –
tELIP ? US 1.00 1.00 0.37 –
rt-PA ? US ? Definity 0.00 0.00 0.00 0.00
1.58 lg/mL
rt-PA ? US 0.87 – – –
tELIP 0.72 0.18 – –
tELIP ? US 1.00 0.92 0.46 –
rt-PA ? US ? Definity 0.00 0.02 0.00 0.00
3.15 lg/mL
rt-PA ? US 0.75 – – –
tELIP 0.25 0.02 – –
tELIP ? US 0.99 0.87 0.06 –
rt-PA ? US ? Definity 0.01 0.19 0.00 0.01
Bold values indicate a significant difference between the treatment arms
Fig. 5 Enzymatic activity of rt-PA released from t-ELIP (solid
squares) and rt-PA (solid circles). The solid, blue line is the linear fit
of activity for rt-PA as a function of rt-PA concentration, and the
dashed, red line is the linear fit of activity for t-ELIP as a function of
rt-PA concentration. For reference, the activity of t-ELIP without the
addition of Triton-X in the spectrophotometric assay is shown 1 lg/
mL rt-PA (open square), and is approximately 59 % of that when
Triton-X is used
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50 % reduction in clot width), but was not more efficacious
than insonation of t-ELIP. However, the thrombolytic ef-
ficacy of t-ELIP exposed to ultrasound was still not higher
than rt-PA alone for all thrombolytic metrics except the
maximum lytic rate. The UH dose of t-ELIP with equiva-
lent activity to rt-PA was less than Definity and greater
than rt-PA at all concentrations of rt-PA.
Discussion
An in vitro model and spectrophotometric assay were
employed to assess stable cavitation emissions and
thrombolytic efficacy associated with several ultrasound-
enhanced treatment schemes. The functional form for clot
width reduction was found to be better described by a
sigmoidally decreasing function, Eq. (2), than an expo-
nentially decreasing function, such as that employed by
Meunier et al. [29]. Bajd et al. [30] also noted that the
instantaneous reduction in clot area was sigmoidal in the
presence of flow. The same group also developed a mole-
cular dynamics model to investigate numerically blood clot
dissolution [31]. Their findings provided theoretical con-
firmation of the sigmoidal decrease of thrombus area ex-
posed to rt-PA under flow.
Exposure of t-ELIP to 120-kHz ultrasound had equiva-
lent thrombolytic efficacy to rt-PA in flow, regardless of
concentration. Shaw et al. [6] found a strong enhancement
of the fractional clot loss for pulsed (80 % duty cycle)
120-kHz exposure of t-ELIP over rt-PA exposed to pulsed
ultrasound. Similarly, Hua et al. (2014) found an increased
efficacy rate for 2-MHz insonations of rt-PA loaded mi-
crobubbles compared to insonation of rt-PA and mi-
crobubbles in a rabbit thrombus model. Shaw et al.
employed a stasis model and had considerably smaller
fractional clot loss for the rt-PA alone treatment compared
to the present flow study (30 % for Shaw et al. vs. 55 % in
the present study, Fig. 3c). Larger fractional clot losses
were found when t-ELIP was exposed to pulsed 120-kHz
ultrasound compared to rt-PA alone in the study of Shaw
et al. (45 % for Shaw et al. vs. 30 % for the present study,
Fig. 3c). In the present study, t-ELIP without ultrasound
exposure had a lower fractional clot loss than rt-PA alone.
It is unknown if the addition of flow to the in vitro model
would affect the uptake of t-ELIP to the thrombus. Re-
gardless, flow appears to be a significant component of the
thrombolytic efficacy of t-ELIP.
Laing et al. [14] found a significant increase in the
maximum percent recanalization of an in vivo rabbit aortic
bFig. 6 Thrombolytic efficacy data for rt-PA, rt-PA and Definity, and
t-ELIP at equivalent enzymatic activity of rt-PA, with and without
intermittent 120-kHz ultrasound exposure (US). aMaximum lytic rate
for all treatment arms determined using Eq. (3), with p values
indicated in Table 4. b Time to 50 % clot width reduction,
determined from Eq. (2), with p values indicated in Table 5.
c Fractional clot loss at the completion of the treatment (30 min),
using Eq. (1), with p values indicated in Table 6. None of the
treatments are statistically different than the all of the other treatment
arms for each rt-PA concentration and thrombolytic metric shown in
a, b, and c. The lipid concentration of t-ELIP is indicated on the top
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thrombus model treated with t-ELIP, or t-ELIP and 6-MHz
duplex (color) Doppler compared to PBS controls.
Similarly, the fractional clot loss, shown in Figs. 3c and 6c,
increased at all concentrations of t-ELIP compared to
plasma controls, except at 0.32 lg/mL rt-PA (8 lg/mL
lipid). Laing et al. found no difference in thrombolytic
enhancement of t-ELIP alone versus t-ELIP exposed to
6-MHz Doppler ultrasound. The data presented in Figs. 3
and 6 is consistent with their findings (p values are pro-
vided in Tables 1, 2, 3, 4, 5, 6). Laing et al. found no
difference between rt-PA and Definity or rt-PA or t-ELIP
exposed to 6-MHz Doppler ultrasound. Like the Laing
study, the present study also showed no difference between
rt-PA or t-ELIP with or without exposure to ultrasound.
However, the present study demonstrated increased
thrombolytic efficacy for rt-PA and Definity exposed to
120-kHz ultrasound in vitro, which is likely due to the
insonation scheme used to promote sustained bubble
activity.
The UH dose of t-ELIP was less than Definity, and
only barely more than the UH dose obtained with rt-PA
alone (Fig. 4). In addition, although an increased concen-
tration of t-ELIP was used to match the rt-PA enzymatic
activity, the ultrasound dose did not increase despite the
increased number of cavitation nucleation sites [32]. UH
emissions are known to correlate with the thrombolytic
efficacy during sonothrombolysis [10, 27]. Liberated gas
from Definity has previously been observed to coalesce
during exposure to 120-kHz ultrasound, resulting in reso-
nant-sized (50 lm), long-lived ([100 s) microbubbles
[10]. Such acoustically active microbubbles were not ob-
served during insonation of t-ELIP.
The reduced cavitation activity may be in part due to the
rapid solubility of the air present in t-ELIP compared to the
low solubility and low diffusivity of perfluorocarbon pre-
sent in Definity [33]. The lipid shell is thought to rupture
during insonation [34], leaving the gas core in direct con-
tact with the surrounding fluid. A micrometer-sized, air-
filled microbubble would dissolve into solution within a
few seconds [35], which is on the order of the transient
time across the clot used in these studies. In contrast,
Definity microbubbles appear to be stable for tens of
Table 4 The Tukey’s HSD test
adjusted p values comparing the
treatment arms for the
maximum lytic rate for
equivalent enzymatic activity of
rt-PA, as shown in Fig. 6a
rt-PA rt-PA ? US tELIP tELIP ? US
0.32 lg/mL
rt-PA ? US 0.99 – – –
tELIP 1.00 1.00 – –
tELIP ? US 0.98 1.00 0.98 –
rt-PA ? US ? Definity 0.04 0.11 0.03 0.04
1.58 lg/mL
rt-PA ? US 1.00 – – –
tELIP 1.00 1.00 – –
tELIP ? US 0.09 0.10 0.26 –
rt-PA ? US ? Definity 0.00 0.00 0.02 0.46
Bold values indicate a significant difference between the treatment arms
Table 5 The Tukey’s HSD test
adjusted p values comparing the
treatment arms for the time to
50 % clot width reduction for
equivalent enzymatic activity of
rt-PA, as shown in Fig. 6b
rt-PA rt-PA ? US tELIP tELIP ? US
0.32 lg/mL
rt-PA ? US 1.00 – – –
tELIP 1.00 1.00 – –
tELIP ? US 0.91 0.83 0.75 –
rt-PA ? US ? Definity 0.31 0.22 0.15 0.57
1.58 lg/mL
rt-PA ? US 1.00 – – –
tELIP 1.00 0.97 – –
tELIP ? US 0.92 0.80 1.00 –
rt-PA ? US ? Definity 0.72 0.55 0.97 0.99
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minutes [33]. The inclusion of a perfluorocarbon gas in
t-ELIP may help to generate the sustained, stable cavitation
activity necessary for thrombolytic enhancement [36].
Given the equivalent thrombolytic efficacy already
achieved between t-ELIP or rt-PA and Definity exposed
to 120-kHz ultrasound, further thrombolytic enhancement
might be expected through incorporation of a perfluoro-
carbon gas in t-ELIP.
The spectrophotometric measurements of the ab-
sorbance of rt-PA are similar to those observed by Smith
et al. [7] (slope of 14.8 DmAbs/min for Smith et al. vs.
13.34 ± 1.77 DmAbs/min for the present study). The 59 %
entrapment efficiency of rt-PA in t-ELIP measured here is
similar to that reported previously [7, 11]. The enzymatic
activity of t-ELIP has previously been investigated [7, 11].
However, these studies did not directly compare t-ELIP
and rt-PA at the same concentration of rt-PA. The distinct
reduction of rt-PA activity from t-ELIP compared to rt-PA
may be due in part to the multiple freeze/thaw steps re-
quired for manufacturing t-ELIP [37]. The enzymatic ac-
tivity of proteins similar to rt-PA have been shown to be
sensitive to freeze–thaw cycling [38].
Thrombolytic-loaded ELIP are typically stored at 5 C
until reconstitution and use, as per typical protocol for
reconstitution of ELIP [32]. The activity of rt-PA is known
to degrade unless stored at -20 to -80 C [39]. Pre-
liminary measurements of t-ELIP activity over time stored
at 5 C shows a slight but insignificant (p[ 0.05) trend for
degradation, as shown in Fig. 7. Similarly, the rt-PA used
in the manufacturing of this t-ELIP was stored at 5 C prior
to incorporation into the lipid, which may have degraded
the enzymatic activity [16].
The in vitro flow model used in this study allowed an in-
depth study of t-ELIP thrombolytic mechanisms. However,
Fig. 7 Enzymatic activity of rt-PA in t-ELIP as a function of storage
at 5 C prior to reconstitution. The solid, red line is a linear fit to the
data, which has an insignificant trend towards decreasing efficacy as a
function of storage date
Table 6 The Tukey’s HSD test
adjusted p values comparing the
treatment arms for fractional
clot loss for equivalent
enzymatic activity of rt-PA, as
shown in Fig. 6c
rt-PA rt-PA ? US tELIP tELIP ? US
0 lg/mL
rt-PA ? US 0.99 – – –
tELIP – – – –
tELIP ? US – – – –
rt-PA ? US ? Definity 0.86 0.93 – –
0.32 lg/mL
rt-PA ? US 1.00 – – –
tELIP 1.00 1.00 – –
tELIP ? US 0.37 0.49 0.41 –
rt-PA ? US ? Definity 0.01 0.02 0.01 0.25
1.58 lg/mL
rt-PA ? US 0.93 – – –
tELIP 0.97 1.00 – –
tELIP ? US 0.43 0.90 0.83 –
rt-PA ? US ? Definity 0.01 0.07 0.05 0.40
Bold values indicate a significant difference between the treatment arms
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several aspects of this in vitro study limit the applicability
of these findings. The low flow rate considered in this
model was fixed, and neglects the contribution of increased
flow rates as the clot lyses. The additional shear stresses
associated with increased flow rates, as would occur
in vivo, have previously been shown to increase the lytic
rate [12]. Only ambient pressure was considered in this
model, which may modify the nonlinear response of mi-
crobubbles compared to hemodynamic pressures in vivo
[40]. Time-varying pressure gradients are known to in-
crease the penetration of thrombolytics in clot samples
[41], thus increasing the degree of clot lysis. The clinical
scenario of an occluding thrombus was not modeled here
[42]. The fibrin targeting capabilities of t-ELIP to clot have
previously been established in vitro [5]. Other thrombolytic
schemes have targeted activated platelets [43] or en-
dothelial-cell-surface determinants [44], and may provide
specificity to thrombi instead of hemostatic plugs. How-
ever, the systemic toxicity and side effects of the treatment
could also not be ascertained in this in vitro model. Further
in vivo studies are needed to assess the potential reduction
of adverse bioeffects in vivo.
Summary
A complex relationship between the enzymatic activity of
rt-PA and the stable cavitation activity necessary to gen-
erate enhanced thrombolysis was determined in an in vitro
flow model. The use of ELIP for ultrasound-enhancement
of thrombolysis requires both a potent thrombolytic and
sufficient nuclei to sustain stable cavitation activity. This
study demonstrated that a novel targeted rt-PA encapsu-
lated agent, t-ELIP, is less effective than a systemic lytic
with a more robust cavitation agent. To maximize the ef-
ficacy of this targeted, encapsulated agent, incorporation of
an insoluble gas that promotes more sustained cavitation
activity is preferred.
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